General Office of National Health Commission of the People's Republic of China, Oncology Branch of the Chinese Medical Association. The Standard for Diagnosis and Treatment of Chinese Colorectal Cancer(2023 Version)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 706-733. DOI: 10.12290/xhyxzz.2023-0315
Citation: General Office of National Health Commission of the People's Republic of China, Oncology Branch of the Chinese Medical Association. The Standard for Diagnosis and Treatment of Chinese Colorectal Cancer(2023 Version)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 706-733. DOI: 10.12290/xhyxzz.2023-0315

The Standard for Diagnosis and Treatment of Chinese Colorectal Cancer(2023 Version)

More Information
  • Received Date: July 02, 2023
  • Accepted Date: July 06, 2023
  • Issue Publish Date: July 29, 2023
  • [1]
    Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71: 209-249. DOI: 10.3322/caac.21660
    [2]
    朱云峰, 陈晓飞. 粪便隐血试验与SDC2基因甲基化检测在结直肠癌筛查中的效果评价[J]. 中国肿瘤, 2022, 31: 723-727. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU202209005.htm
    [3]
    乐晨琴, 刘成成, 胡烨婷, 等. 美国一般风险人群结直肠癌筛查指南更新解读[J]. 中华胃肠外科杂志, 2022, 25: 826-833.
    [4]
    中国抗癌协会家族遗传性肿瘤专业委员会. 中国家族遗传性肿瘤临床诊疗专家共识(2021年版)(4): 家族遗传性结直肠癌[J]. 中国肿瘤临床, 2022, 49: 1-5. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL202214007.htm
    [5]
    Diagnosis And Treatment Guidelines For Colorectal Cancer Working Group C. Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)[J]. Chin J Cancer Res, 2019, 31: 117-134. DOI: 10.21147/j.issn.1000-9604.2019.01.07
    [6]
    Li J, Yuan Y, Yang F, et al. Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)[J]. J Hematol Oncol, 2019, 12: 16. DOI: 10.1186/s13045-019-0702-0
    [7]
    Beets-Tan R, Lambregts D, Maas M, et al. Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting[J]. Eur Radiol, 2018, 28: 1465-1475. DOI: 10.1007/s00330-017-5026-2
    [8]
    Rouleau Fournier F, Motamedi M, Brown CJ, et al. Oncologic outcomes associated with MRI-detected Extramural Venous Invasion (mrEMVI) in rectal cancer: a systematic review and meta-analysis[J]. Ann Surg, 2022, 275: 303-314. DOI: 10.1097/SLA.0000000000004636
    [9]
    Hoendervangers S, Burbach J, Lacle MM, et al. Patholo-gical complete response following different neoadjuvant treatment strategies for locally advanced rectal cancer: a systematic review and meta-analysis[J]. Ann Surg Oncol, 2020, 27: 4319-4336. DOI: 10.1245/s10434-020-08615-2
    [10]
    Park SH, Cho SH, Choi SH, et al. MRI assessment of complete response to preoperative chemoradiation therapy for rectal cancer: 2020 guide for practice from the Korean society of abdominal radiology[J]. Korean J Radiol, 2020, 21: 812-828. DOI: 10.3348/kjr.2020.0483
    [11]
    Muaddi H, Silva S, Choi WJ, et al. When is a ghost really gone? A systematic review and meta-analysis of the accuracy of imaging modalities to predict complete pathological response of colorectal cancer liver metastases after chemotherapy[J]. Ann Surg Oncol, 2021, 28: 6805-6813. DOI: 10.1245/s10434-021-09824-z
    [12]
    Tsili AC, Alexiou G, Naka C, et al. Imaging of colorectal cancer liver metastases using contrast-enhanced US, multidetector CT, MRI, and FDG PET/CT: a meta-analysis[J]. Acta Radiol, 2021, 62: 302-312. DOI: 10.1177/0284185120925481
    [13]
    O'Connell E, Galvin R, McNamara DA, et al. The utility of preoperative radiological evaluation of early rectal neoplasia: a systematic review and meta-analysis[J]. Colorectal Dis, 2020, 22: 1076-1084. DOI: 10.1111/codi.15015
    [14]
    Liu W, Zhang ZY, Yin SS, et al. Contrast-enhanced intraoperative ultrasound improved sensitivity and positive predictive value in colorectal liver metastasis: a systematic review and meta-analysis[J]. Ann Surg Oncol, 2021, 28: 3763-3773. DOI: 10.1245/s10434-020-09365-x
    [15]
    Mirshahvalad SA, Hinzpeter R, Kohan A, et al. Diagnostic performance of [18F]-FDG PET/MR in evaluating colorectal cancer: a systematic review and meta-analysis[J]. Eur J Nucl Med Mol Imaging, 2022, 49: 4205-4217. DOI: 10.1007/s00259-022-05871-0
    [16]
    Steele SR, Chang GJ, Hendren S, et al. Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer[J]. Dis Colon Rectum, 2015, 58: 713-725. DOI: 10.1097/DCR.0000000000000410
    [17]
    Blomqvist L, Holm T, Göranson H, et al. MR imaging, CT and CEA scintigraphy in the diagnosis of local recurrence of rectal carcinoma[J]. Acta Radiol, 1996, 37: 779-784. DOI: 10.1177/02841851960373P270
    [18]
    Pema PJ, Bennett WF, Bova JG, et al. CT vs MRI in diagnosis of recurrent rectosigmoid carcinoma[J]. J Comput Assist Tomogr, 1994, 18: 256-261. DOI: 10.1097/00004728-199403000-00016
    [19]
    Schaefer O, Langer M. Detection of recurrent rectal cancer with CT, MRI and PET/CT[J]. Eur Radiol, 2007, 17: 2044-2054. DOI: 10.1007/s00330-007-0613-2
    [20]
    Colosio A, Fornès P, Soyer P, et al. Local colorectal cancer recurrence: pelvic MRI evaluation[J]. Abdom Imaging, 2013, 38: 72-81. DOI: 10.1007/s00261-012-9891-5
    [21]
    Guillem JG, Minsky BD. Extended perineal resection of distal rectal cancers: surgical advance, increased utilization of neoadjuvant therapies, proper patient selection or all of the above?[J]. J Clin Oncol, 2008, 26: 3481-3482. DOI: 10.1200/JCO.2007.15.6646
    [22]
    Kusters M, Marijnen CA, van de Velde CJ, et al. Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial[J]. Eur J Surg Oncol, 2010, 36: 470-476. DOI: 10.1016/j.ejso.2009.11.011
    [23]
    Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment[J]. Ann Oncol, 2010, 21 Suppl 5: v93-v97.
    [24]
    Kaur H, Choi H, You YN, et al. MR imaging for preoperative evaluation of primary rectal cancer: practical considerations[J]. Radiographics, 2012, 32: 389-409. DOI: 10.1148/rg.322115122
    [25]
    Patel UB, Taylor F, Blomqvist L, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience[J]. J Clin Oncol, 2011, 29: 3753-3760. DOI: 10.1200/JCO.2011.34.9068
    [26]
    Battersby NJ, How P, Moran B, et al. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY Ⅱ study[J]. Ann Surg, 2016, 263: 751-760. DOI: 10.1097/SLA.0000000000001193
    [27]
    Bamba Y, Itabashi M, Kameoka S. Preoperative evaluation of the depth of anal canal invasion in very low rectal cancer by magnetic resonance imaging and surgical indications for intersphincteric resection[J]. Surg Today, 2012, 42: 328-333. DOI: 10.1007/s00595-011-0007-6
    [28]
    Shihab OC, How P, West N, et al. Can a novel MRI staging system for low rectal cancer aid surgical planning?[J]. Dis Colon Rectum, 2011, 54: 1260-1264. DOI: 10.1097/DCR.0b013e31822abd78
    [29]
    Fernandes MC, Gollub MJ, Brown G. The importance of MRI for rectal cancer evaluation[J]. Surg Oncol, 2022, 43: 101739. DOI: 10.1016/j.suronc.2022.101739
    [30]
    Shaukat A, Kaltenbach T, Dominitz JA, et al. Endoscopic recognition and management strategies for malignant colorectal polyps: recommendations of the US Multi-Society Task Force on olorectal Cancer[J]. Gastroenterology, 2020, 159: 1916-1934. e2. DOI: 10.1053/j.gastro.2020.08.050
    [31]
    Choi JY, Jung SA, Shim KN, et al. Meta-analysis of predictive clinicopathologic factors for lymph node metastasis in patients with early colorectal carcinoma[J]. J Korean Med Sci, 2015, 30: 398- 406.
    [32]
    Tanaka S, Kashida H, Saito Y, et al. Japan gastroenterological endoscopy society guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection[J]. Dig Endosc, 2020, 32: 219-239. DOI: 10.1111/den.13545
    [33]
    Matsuda T, Fukuzawa M, Uraoka T, et al. Risk of lymph node metastasis in patients with pedunculated type early invasive colorectal cancer: a retrospective multicenter study[J]. Cancer Sci, 2011, 102: 1693-1697. DOI: 10.1111/j.1349-7006.2011.01997.x
    [34]
    Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76: 182-188. DOI: 10.1111/his.13975
    [35]
    Benson AB, Venook AP, Al-Hawary MM, et al. Rectal Cancer, Version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20: 1139-1167. DOI: 10.6004/jnccn.2022.0051
    [36]
    Pimentel-Nunes P, Libânio D, Bastiaansen B, et al. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline-Update 2022[J]. Endoscopy, 2022, 54: 591-622. DOI: 10.1055/a-1811-7025
    [37]
    Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016[J]. Mod Pathol, 2017, 30: 1299-1311. DOI: 10.1038/modpathol.2017.46
    [38]
    Martelli V, Pastorino A, Sobrero AF. Prognostic and predictive molecular biomarkers in advanced colorectal cancer[J]. Pharmacol Ther, 2022, 236: 108239. DOI: 10.1016/j.pharmthera.2022.108239
    [39]
    Wang J, Yi Y, Xiao Y, et al. Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcino-ma with hypermethylated MLH1 and wild-type BRAF and KRAS[J]. Mod Pathol, 2019, 32: 1053-1064. DOI: 10.1038/s41379-019-0212-1
    [40]
    Weiser MR. AJCC 8th Edition: Colorectal Cancer[J]. Ann Surg Oncol, 2018, 25: 1454-1455. DOI: 10.1245/s10434-018-6462-1
    [41]
    Sabiston DC. Sabiston textbook of surgery[M]. 20 ed. Amsterdam: Elsevier, 2016.
    [42]
    顾晋. 结直肠癌外科手术的切缘[J]. 中华胃肠外科杂志, 2022, 25: 36-39.
    [43]
    Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery-the clue to pelvic recurrence?[J]. Br J Surg, 1982, 69: 613-616.
    [44]
    关旭, 王锡山. 结直肠肿瘤经自然腔道取标本手术的器官功能保护优势[J]. 中华胃肠外科杂志, 2022, 25: 500-504.
    [45]
    Yuan Z, Weng S, Ye C, et al. CSCO guidelines for colorectal cancer version 2022: Updates and discussions[J]. Chin J Cancer Res, 2022, 34: 67-70. DOI: 10.21147/j.issn.1000-9604.2022.02.01
    [46]
    Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer[J]. N Engl J Med, 2022, 386: 2363-2376. DOI: 10.1056/NEJMoa2201445
    [47]
    Hu H, Kang L, Zhang J, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7: 38-48. DOI: 10.1016/S2468-1253(21)00348-4
    [48]
    Grothey A, Sobrero AF, Shields AF, et al. Duration of adjuvant chemotherapy for stage Ⅲ colon cancer[J]. N Engl J Med, 2018, 378: 1177-1188. DOI: 10.1056/NEJMoa1713709
    [49]
    Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial[J]. JAMA, 2018, 319: 2486-2496. DOI: 10.1001/jama.2018.7855
    [50]
    Xu RH, Muro K, Morita S, et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial[J]. Lancet Oncol, 2018, 9: 670-671.
    [51]
    André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer[J]. N Engl J Med, 2020, 83: 2207-2218.
    [52]
    Li J, Deng Y, Zhang W, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors[J]. J Hematol Oncol, 2021, 14: 95. DOI: 10.1186/s13045-021-01095-1
    [53]
    Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials[J]. Lancet Oncol, 2020, 21: 531-540. DOI: 10.1016/S1470-2045(19)30856-3
    [54]
    Chen G, Peng J, Xiao Q, et al. Postoperative circulating tumor DNA as markers of recurrence risk in stages Ⅱ to Ⅲ colorectal cancer[J]. J Hematol Oncol, 2021, 14: 80. DOI: 10.1186/s13045-021-01089-z
    [55]
    Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage Ⅱ colon cancer[J]. N Engl J Med, 2022, 386: 2261-2272. DOI: 10.1056/NEJMoa2200075
    [56]
    Fakih MG, Kopetz S, Kuboki Y, et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial[J]. Lancet Oncol, 2022, 23: 115-124. DOI: 10.1016/S1470-2045(21)00605-7
    [57]
    Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-Mutated colorectal cancer[J]. N Engl J Med, 2019, 381: 1632-1643. DOI: 10.1056/NEJMoa1908075
    [58]
    Strickler JH, Yoshino T, Graham RP, et al. Diagnosis and treatment of ERBB2-Positive metastatic colorectal cancer: a review[J]. JAMA Oncol, 2022, 8: 760-769. DOI: 10.1001/jamaoncol.2021.8196
    [59]
    Fokas E, Allgäuer M, Polat B, et al. Rando mized phase Ⅱ trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12[J]. J Clin Oncol, 2019, 37: 3212-3222. DOI: 10.1200/JCO.19.00308
    [60]
    Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy[J]. J Clin Oncol, 2022, 40: 2546-2556.
    [61]
    Jin J, Tang Y, Hu C, et al. Multicenter, randomized, phase Ⅲ trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)[J]. J Clin Oncol, 2022, 40: 1681-1692. DOI: 10.1200/JCO.21.01667
    [62]
    Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22: 29-42. DOI: 10.1016/S1470-2045(20)30555-6
    [63]
    Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22: 702-715. DOI: 10.1016/S1470-2045(21)00079-6
    [64]
    Bando H, Tsukada Y, Inamori K, et al. Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer[J]. Clin Cancer Res, 2022, 28: 1136-1146. DOI: 10.1158/1078-0432.CCR-21-3213
    [65]
    Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers[J]. Nat Med, 2020, 26: 566-576. DOI: 10.1038/s41591-020-0805-8
    [66]
    Lin Z, Cai M, Zhang P, et al. Phase Ⅱ, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer[J]. J Immunother Cancer, 2021, 9: e003554. DOI: 10.1136/jitc-2021-003554
    [67]
    Rahma OE, Yothers G, Hong TS, et al. Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial[J]. JAMA Oncol, 2021, 7: 1225-1230. DOI: 10.1001/jamaoncol.2021.1683
    [68]
    Fernandez LM, São Julião GP, Figueiredo NL, et al. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study[J]. Lancet Oncol, 2021, 22: 43-50. DOI: 10.1016/S1470-2045(20)30557-X
    [69]
    Fokas E, Appelt A, Glynne-Jones R, et al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer[J]. Nat Rev Clin Oncol, 2021, 18: 805-816. DOI: 10.1038/s41571-021-00538-5
    [70]
    Peters FP, Teo M, Appelt AL, et al. Mesorectal radiother-apy for early stage rectal cancer: a novel target volume[J]. Clin Transl Radiat Oncol, 2020, 21: 104-111. DOI: 10.1016/j.ctro.2020.02.001
    [71]
    Zhu J, Liu A, Sun X, et al. Multicenter, randomized, phase Ⅲ trial of neoadjuvant chemoradiation with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer[J]. J Clin Oncol, 2020, 38: 4231-4239. DOI: 10.1200/JCO.20.01932
    [72]
    Garant A, Vasilevsky CA, Boutros M, et al. MORPHEUS Phase Ⅱ-Ⅲ study: a pre-planned interim safety analysis and preliminary results[J]. Cancers (Basel), 2022, 14: 3665. DOI: 10.3390/cancers14153665
    [73]
    Das P, Delclos ME, Skibber JM, et al. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation[J]. Int J Radiat Oncol Biol Phys, 2010, 77: 60-65. DOI: 10.1016/j.ijrobp.2009.04.056
    [74]
    Tao R, Tsai CJ, Jensen G, et al. Hyperfractionated accelerated reirradiation for rectal cancer: an analysis of outcomes and toxicity[J]. Radiother Oncol, 2017, 122: 146-151. DOI: 10.1016/j.radonc.2016.12.015
  • Cited by

    Periodical cited type(0)

    Other cited types(1)

Catalog

    Article Metrics

    Article views (14368) PDF downloads (7191) Cited by(1)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close